Ergomed logo

ERGO - Ergomed News Story

685p -5.0  -0.7%

Last Trade - 9:22am

Sector
Healthcare
Size
Small Cap
Market Cap £334.0m
Enterprise Value £325.2m
Revenue £68.3m
Position in Universe 625th / 1807

Ergomed plc - Notice of Interim Results

Fri 14th September, 2018 7:01am
RNS Number : 7548A
Ergomed plc
14 September 2018
 

PRESS RELEASE

FOR IMMEDIATE RELEASE

 

Notice of Interim Results

 

London, UK - 14 September 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, will announce its interim results for the six months ended 30 June 2018 on Wednesday 19th September 2018.

 

Stephen Stamp, Chief Executive Officer and Stuart Jackson, Chief Financial Officer, will host a presentation and conference call for analysts at 8:30am BST on the day of the results at the offices of Numis Securities, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT.

 

ENDS

 

Enquiries:

 

Ergomed plc

Tel: +44 (0) 1483 503 205

Stephen Stamp (Chief Executive Officer)

Stuart Jackson (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)


James Black (Joint Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Matthew Neal / Olivia Manser

ergomed@consilium-comms.com



MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke


 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORDBGDCUBBBGIX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.